Category: Press Release
-
Ratio Therapeutics Announces the Appointment of Kenan Turnacioglu to its Board of Directors
BOSTON, MA September 17, 2026 — Ratio Therapeutics Inc. (“Ratio”) a clinical-stage pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment, today announced the appointment of Kenan Turnacioglu, Ph.D., to its Board of Directors. Dr. Turnacioglu brings more than two decades of experience spanning healthcare investing, biotechnology company building, oncology and corporate…
-
Ratio Therapeutics Enters into Research Collaboration and License Agreement with RayzeBio to Advance a Novel Radiopharmaceutical Program
Collaboration brings together complementary expertise and proprietary technologies to advance a next-generation radiopharmaceutical candidate with the potential to enhance tumor targeting. BOSTON, MA, September 9, 2026 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment, today announced that it has entered into a research collaboration and…
-
Ratio Therapeutics Closes $70 Million Series C Financing to Advance Clinical Development of Targeted Radiotherapeutics Pipeline and Expand Manufacturing Infrastructure
Round brings total capital raised to over $240 Million. BOSTON, MA July 31, 2026 – Ratio Therapeutics, Inc. (Ratio), a clinical-stage pharmaceutical company developing best-in-class radiopharmaceuticals for cancer treatment, today announced the closing of a $70 million Series C financing. The financing included strong participation from existing investors Duquesne Family Office and Bristol Myers Squibb, along with…
-
Ratio Therapeutics Enters Strategic Actinium-225 Supply Agreement with PanTera to Support Radiopharmaceutical Development Programs
Collaboration strengthens Ratio’s long-term isotope supply strategy for clinical development and future pipeline growth BOSTON, MA, June 30, 2026 – Ratio Therapeutics Inc. (Ratio), a clinical-stage pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment, today announced that it has entered into a strategic supply agreement with PanTera, an innovative producer scaling the supply…
-
Ratio Therapeutics and PharmaLogic Expand Manufacturing Collaboration to Support Clinical Development of [Ac-225]RTX-2358
Expanded collaboration adds manufacturing capacity, strengthens redundancy, and supports later-stage development planning for Ratio’s lead FAP-targeted radiotherapeutic candidate BOSTON, May 29, 2026 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment, today announced an expanded manufacturing collaboration with PharmaLogic Holdings Corp. (PharmaLogic), a leading contract development and manufacturing…
-
Ratio Therapeutics Appoints Global Medical Leader Colin Hayward as Chief Medical Officer
BOSTON, March 12, 2026 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced the appointment of Colin Hayward, MBBS, FFPM, as the company’s Chief Medical Officer. Dr. Hayward brings more than 26 years of global experience in the healthcare industry, including leadership in…
-
Ratio Therapeutics has successfully dosed the first cohort in its Phase 1/2 study evaluating a novel FAP-targeted radiopharmaceutical in patients with late-stage aggressive sarcomas
BOSTON, MA, December 16, 2025 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, announced today that dosing of the first cohort has been completed in the ATLAS trial, a Phase 1/2 open-label study evaluating the safety, tolerability, and efficacy of the company’s lead…
-
Ratio Therapeutics Announces the Appointment of Marcel Reichen as Chief Strategy Officer
BOSTON, November 4, 2025 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced the appointment of Marcel Reichen, Ph.D., MBA, as the company’s Chief Strategy Officer. Dr. Reichen brings over a decade of international experience in the pharmaceutical and radioligand therapy (RLT) industries,…
-
Ratio Therapeutics and TerraPower Isotopes Sign Supply Agreement for Actinium-225 For Targeted Radiotherapeutics
BOSTON and BELLEVUE, WA, June 20, 2025 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, and TerraPower Isotopes, a subsidiary of TerraPower, a leading nuclear innovation company, today announced they entered into a supply agreement for the medical radioisotope actinium-225 (Ac-225)1. Under the agreement,…
-
June 17th, 2025: Ratio Therapeutics and Nusano Enter Long-Term, Multi-Isotope Supply Agreement to Boost Production of Cancer Radiopharmaceuticals
BOSTON and WEST VALLEY CITY, Utah – June 17, 2025 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, and Nusano, a physics company enabling breakthrough radioisotope supplies, today announced a long-term supply agreement designed to support the Ratio’s product pipeline and enable innovation.…